Endoscopic hemoclip treatment for bleeding peptic ulcer

Lai YC, Yang SS, Wu CH and Chen TK

INTRODUCTION

Upper gastrointestinal bleeding is a frequently encountered clinical problem for both the endoscopist and surgeon[1]. Acute hemorrhage from duodenal and gastric ulcers stops spontaneously in approximately 70% to 80% of cases[2]. The remaining patients represent a high risk group requiring prompt identification and treatment to improve the high morbidity and death rate. The consensus is that patients who have peptic ulcer with spurting or oozing hemorrhage need active treatment[3-4]. The death rate of patients with persistent or recurrent bleeding is 12% to 18%[5-8].

There have been many endoscopic techniques, including thermal application (laser, heater probe, and bicap) and local injection (hypertonic saline, epinephrine, and ethanol), advocated effectively for the control of gastrointestinal bleeding[9]. But, their results vary depending on the operators or the patients[10,11]. Although the success rate of initial hemostasis is high, rebleeding has been reported to occur in 10% to 30% of patients[12-14]. Thermal methods and injection of hemostatic agents can cause tissue injury leading to necrosis and possible perforation[15-16]. Mechanical hemostasis by the application of a metal hemoclip to a bleeding vessel is an appealing alternative to the currently available techniques. It was first introduced in 1975 by Hayashi et al[18]. However, the initial experience was discouraging because of its complexity and low retention rate. In 1988, Hachisu introduced a modified hemoclip for upper gastrointestinal hemorrhage with a permanent hemostatic rate of 84.3%[19]. A newly improved rotatable clip-device with better grasping capability has been developed recently, which can make the procedure easier and save much time[20]. We therefore used this newly improved metallic clip to prospectively evaluate its role in the hemostatic effect on bleeding peptic ulcers.

MATERIALS AND METHODS

From January 1997 to December 1998, totally 40 hospitalized patients were enrolled. All patients were proved to have active hemorrhage from peptic ulcer by endoscopic examination at Cathay General Hospital. All cases had F1a (spurting) or F1b (oozing) hemorrhagic activity by Forrest classification[21]. Patients who had multiple bleeding sites or gastric cancer were excluded. Since active hemostatic treatment has been recommended...
for acute bleeding from the upper gastrointestinal tract\cite{3,4}, the present study did not include a control group which was treated conservatively.

Endoscopies were carried out using an Olympus GIF-XQ 200 endoscope (Olympus Corp., Tokyo, Japan). We used a hemoclip (MD 850, Olympus) device, which has a new rotatable clip-device (HX-5LR-1, Olympus) for hemostasis. The hemoclip was applied directly to the bleeding vessel. Vessels traversing the surface were clipped at both ends of the bleeding point. Initial hemostasis was defined as no bleeding from the ulcer for at least 5 minutes.

Patients were treated with intravenous \( \text{H}_2 \)-blockers and oral antacid suspensions after endoscopic examination. A nasogastric tube was inserted to observe the bleeding condition. Blood transfusion was given if the hemoglobin level dropped to less than 90 mg/L, or if vital signs deteriorated.

Shock was defined as systolic blood pressure less than 13.3 kPa (100 mmHg) and a pulse rate greater than 100 beats/min, accompanied by pallor, cold sweating, and oliguria. Rebleeding or recurrent bleeding was defined as blood in the stomach 24 h after treatment, presence of unstable vital signs, and continuous tarry or bloody stools, or hematemeses after treatment.

Endoscopic examination was performed again whenever there was evidence or suspicion of rebleeding. Humoclip were used again if necessary and feasible. Surgical intervention was considered if re-clip still could not control the bleeding. Ultimate hemostasis was defined as lack of rebleeding for 7 days after treatment. Follow-up endoscopy was performed 1 week after initial hemoclip treatment if patients agreed.

We used Student's \( t \) test or Wilcoxon 2-sample test for the analysis of continuous variables. Chi-square test and Fisher's exact test were applied for the analysis of nominal variables. A \( P \) value of less than 0.05 was considered significant.

RESULTS

Totally, 40 patients were included in this study over a 2-year period. There were 29 males and 11 females with a mean age of 62.3±3.3 years (range 26-85 years). Locations of peptic ulcers and their hemorrhagic activity by Forrest classification are listed in Table 1.

Two of our 40 cases failed to terminate hemorrhage in response to hemoclips. One failed case was due to torrential active bleeding from the posterior wall of the mid-gastric body, which prevented treatment feasibility. This patient subsequently received surgical intervention. Another case with F1a activity had hemorrhage from the lesser curvature of the high gastric body, which made clipping difficult to perform, and we were unable to clip this area efficiently. The patient could not undergo surgery due to end-stage renal disease and sepsis, and he expired in spite of treatment. Rebleeding after hemoclip treatment occurred in three cases. The first patient had chronic liver disease, diabetes mellitus, and renal insufficiency. He had a gastric ulcer (F1b) on the posterior wall of the high body, where the application of clipping was difficult. Massive hemorrhage occurred red 2 days after the first endoscopic clipping. Emergent operation was performed and clips were found to have dislodged during the operation. The second patient underwent anti-coagulant treatment for rheumatic heart disease. He had a gastric ulcer (F1a) on the lesser curvature of the antrum. Follow-up endoscopy revealed active oozing from the edge of the clips. Re-clipping successfully stopped the hemorrhage. The third case had a duodenal ulcer (F1a) on the posterior wall. Follow-up endoscopy revealed that the clip had dislodged. The rebleeding rates of F1a and F1b subgroups were 15% and 4%, respectively (Table 2). This difference is not statistically significant.

The final results of our study are shown in Table 3. The overall hemostatic rate was 93%. In patients with F1a ulcers, the rate was 87%, and in F1b ulcers was 96%; the difference between them is not significant. Two cases received emergent operation, and their post-operative courses were smooth and uneventful. Mortality occurred in only one patient who had serious underlying disease (end-stage renal disease and sepsis) and was unable to receive surgical intervention.

Table 4 shows the relationship between shock and the rebleeding rate. After hemoclipping, the rebleeding rate in the F1a shock subgroup was 20%, a rate not different from that 13% in the F1a non-shock subgroup. In the F1b group, the rebleeding rates did not differ between the shock and non shock groups (17% versus 0%, \( P = 0.07 \)). In those patients without shock, the hemostatic rate was 100% in both F1a and F1b subgroups. In patients with shock, the hemostatic rates after hemoclipping were 71% in F1a cases and 83% in F1b cases (Table 5).

The number of clips used per patient in each subgroup is shown in Table 6. The average number of clips used in all cases was 3.0 (range 2-5). The average number was higher in the F1a subgroup (3.4, including gastric and duodenal ulcers) than in the F1b subgroup (2.8, including gastric, duodenal, and marginal ulcers, \( p = 0.04 \) by Wilcoxon 2-sample test). The number of clips (including F1a and F1b) did not differ between gastric and duodenal ulcers. We also tried to analyze the difference of clip number used in various locations of gastric and duodenum ulcers, but were unable to reach any definite conclusion because of limited case numbers.
TABLE 1  Number of patients by ulcer type and Forrest classification

| Type             | F1a (n = 15) | F1b (n = 25) |
|------------------|-------------|-------------|
| Gastric ulcer    | 10          | 14          |
| Duodenal ulcer   | 5           | 9           |
| Marginal ulcer   | 0           | 2           |
| Total            | 15          | 25          |

Table 2  Number of rebleeding cases in each subgroup

| Type             | F1a (n = 15) | F1b (n = 25) |
|------------------|-------------|-------------|
| Gastric ulcer    | 1/8^        | 1/14        |
| Duodenal ulcer   | 1/5         | 0/9         |
| Marginal ulcer   | 0/0         | 0/2         |
| Total            | 2/13^       | 1/25        |

Data are expressed as rebleeding/subgroup case number. ^Two cases without initial hemostasis are excluded. \( P = 0.27. \)

Table 3  Outcome of endoscopic hemoclip treatment

| Treatment        | F1a (n = 15) | F1b (n = 25) | Total (n = 40) |
|------------------|-------------|-------------|-----------|
| Ultimate hemostasis\(^a\) | 13(87%)    | 24(96%)    | 37(93%)  |
| Emergent surgery | 1           | 1           | 2(5%)    |
| Mortality        | 1           | 0           | 1(3%)    |

Data are presented as case number (percentage). ^Two patients with re-clipping are included. \( P = 0.07 \).

Table 4  The relationship between shock and rebleeding rate

| Subgroup        | F1a (n = 5) | F1b (n = 9) |
|-----------------|-------------|-------------|
| Shock           | 1/5(20%)    | 1/6(17%)    |
| Non-shock       | 1/8(13%)    | 0/9(0%)     |

Data are expressed as rebleeding/subgroup case number. ^Two cases without initial hemostasis are excluded. \( P = 0.77; P = 0.07 \) compared with non-shock subgroups.

Table 5  The relationship between shock and ultimate hemostatic rate

| Subgroup        | F1a (n = 15) | F1b (n = 25) |
|-----------------|-------------|-------------|
| Shock           | 5/7(71%)\(^a\) | 5/6(83%)\(^b\) |
| Non-shock       | 8/8(100%)   | 19/19(100%) |

Data are expressed as ultimate hemostasis/subgroup case number. \( P = 0.11; P = 0.07 \) compared with non-shock subgroups.

Table 6  Number of clips used per case in different subgroups

| Type             | F1a (n = 8) | F1b (n = 25) |
|------------------|-------------|-------------|
| Gastric ulcer    | 3.5         | 2.9         |
| Duodenal ulcer   | 3.2         | 2.7         |
| Marginal ulcer   | 3.4         | 2.5         |
| Average\(^a\)    | 3.4         | 2.8         |

\( P = 0.04. \)

DISCUSSION

The rotatable clip-device we used was developed in 1995. This device has a dial at the center of the handle, which can rotate the clip and open at the tip of the device. The working length of HX-5LR-1 is 165 cm for an upper GI endoscope. Use of a special wire resistant to rotational distortion and a special coating facilitate rotation of the clips and markedly reduce the force required for clipping, as compared to the conventional device (HX-3/4 clip-device). As a result, precise clipping with application of a smaller force has become possible\(^{20}\). HX-5LR-1 has advantages over the older HX-3/4 clip-device in its rotatability, which can make clipping more accurate, and its durability including the ability to withstand sterilization by autoclaving\(^{20}\).

Mechanical clipping of a bleeding ulcer is appealing because the bleeding can be stopped immediately\(^{22}\). This technique was once abandoned due to its complexity. In 1993, Binmoeller et al in Germany evaluated an improved metallic clip for endoscopic treatment of non-variceal hemorrhage from various sources in the upper gastrointestinal tract and concluded its highly effective hemostatic effect\(^{9}\). Our results confirm the efficacy and safety of hemoclips for the treatment of peptic ulcer with active hemorrhage.

It is well recognized that about 50% of high risk patients have continuous hemorrhage or rebleeding during hospitalization\(^{23}\). In our cases, hemoclip treatment reduced the rates of rebleeding to 15% in the F1a subgroup and 4% in the F1b subgroup. The ultimate hemostasis rate was 93%. The tangential application of clips is sometimes difficult, which is the same as for other therapeutic endoscopic modalities (e.g. laser or injection therapy). Application of clips should ideally be performed while approaching the bleeding spot en face\(^{22}\). In two of our patients who failed to terminate the hemorrhage by using hemoclip treatment, the locations of the ulcers were such that it was difficult to use an en face approach.

Dislodging of clips is another cause of rebleeding. Two of our patients had clips which dislodged, one on the posterior wall of the high gastric body and another on the posterior wall of the duodenal bulb. The locations of the ulcers were difficult to approach when applying the clips. Underlying diseases with bleeding tendency may influence the effect of endoscopic hemostatic procedure\(^{24}\). In one patient with ooze from the site of clipping, the hemorrhage might be related in part to the use of anti-coagulant medications.

In those patients with hemorrhage from the upper gastrointestinal tract, the presence of shock on admission and visible vessel significantly predict rebleeding\(^{1,25,26}\). Hsu et al reported that an adherent clot associated with hypovolemic shock had a 50% rebleeding rate. On the contrary, the presence of a clot without hypovolemic shock had a rebleeding rate of only 17%. Non-bleeding visible vessel associated with shock had a 40% rebleeding rate; without shock it decreased to 25%\(^{17}\). The presentation of active hemorrhage, shock on admission, and low hemoglobin concentration predict a poor outcome\(^{23}\). In our series, neither the rebleeding rate nor the ultimate hemostatic rate was influenced by the presence of shock. In our study, the F1a with shock subgroup had the highest rebleeding rate of only 20%, which suggests that endoscopic hemoclipping be a useful and effective...
hemostatic method.

Clipping allows clamping of bleeding vessels and achieves mechanical sealing without affecting the ulcer’s depth or size. Clips dislodge spontaneously and pass through the gastrointestinal tract safely within 3 weeks\(^2\). The damage to surrounding tissue was reported to be limited\(^{27,28}\). In the present study, follow-up endoscopy showed no obvious clip-related tissue injury or impairment of ulcer healing. Our findings confirm that no obvious complications resulted from clip placement.

Both heater probe and injection therapies are widely used. Their hemostatic rates are about 75% to 95%\(^{1,2,5,29,30}\). Our study shows that the hemostatic effect of hemoclips is 93% in peptic ulcers, which is comparable to the above reports. Our data are consistent with those of Takahashi’s in which the outcomes of bleeding ulcers did not differ between injection and hemoclipping\(^3\).

The number of clips required for hemostasis depends on the bleeding activity, endoscopic accessibility of the bleeding site, and the characteristics of the vessel\(^6\). Spurting lesions generally require more clips to achieve hemostasis than do oozing lesions. In our series, the average number of clips was higher in the F1a subgroup than in the F1b subgroup. Our results are comparable to the number of Binmoeller et al, who used an average of 3.2 clips per case for spurting bleeders and 2.7 clips for oozing bleeders\(^9\).

In conclusion, endoscopic hemoclip treatment for bleeding peptic ulcer is an effective and safe modality. It has a high initial hemostatic rate (95%) and a low rebleeding rate (8%). Ultimate hemostasis reached 93% in our study with no obvious complications. With the development of newly developed clips and clip application devices, the endoscopic hemoclip treatment has become easier and much more efficient. Endoscopic hemoclip treatment deserves further comparative studies with other hemostatic methods.

REFERENCES
1 Steffes CP, Sugawa C. Endoscopic management of nonvariceal gastrointestinal bleeding. World J Surg, 1992;16:1025-1033
2 Sugawa C, Joseph AL. Endoscopic interventional management of bleeding duodenal and gastric ulcers. Surg Clin North Am, 1992;72:317-334
3 Consensus Conference. Therapeutic endoscopy and bleeding ulcers. JAMA, 1989;262:1369-1372
4 Lin HJ, Perng CL, Lee FY. Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessel; a prospective study. Gut, 1994;35:1389-1393
5 Hsu PI, Lee KH, Lin XZ. When to discharge patients with bleeding peptic ulcers: a prospective study of residual risk of rebleeding. Gastrointest Endosc, 1996;44:382-387
6 Lin HJ, Chan FY, Lee ZC. Endoscopic injection to arrest peptic ulcer hemorrhage: a prospective, randomized controlled trial: preliminary results. Hepatogastroenterology, 1991;38:291-294
7 Hsu PI, Lin XZ, Chan SH. Bleeding peptic ulcer-risk factors for rebleeding and sequential changes in endoscopic findings. Gut, 1994;35:746-749
8 Wara P. Endoscopic prediction of major rebleeding—a prospective study of stigmata of hemorrhage in bleeding ulcer. Gastroenterology, 1985;88:1209-1214
9 Binmoeller KF, Thanke F, Soehendra N. Endoscopic hemoclip treatment for gastrointestinal bleeding. Endoscopy, 1993;25:167-170
10 Laurence BH, Cotton PB. Bleeding gastroduodenal ulcers: nonoperative treatment. World J Surg, 1987;11:198-203
11 Steele RJC. Endoscopic hemostasis for non-variceal upper gastrointestinal hemorrhage. Br J Surg, 1989;76:219-225
12 Chung SCS, Leung JWC, Sung JY. Injection or heat probe for bleeding ulcer. Gastroenterology, 1991;100:33-37
13 Waring J, Sanawski RA, Sawyer RL. A randomized comparison of multipolar electrocoagulation and injection sclerosis for the treatment of bleeding peptic ulcer. Gut, 1993;37:275-278
14 Hui WM, Ng MMT, Lok ASF. A randomized comparison of laser photo coagulation, heater probe, and bipolar electrocoagulation in the treatment of actively bleeding ulcers. Gastrointest Endosc, 1991;37:299-304
15 Rutgeerts P, Geboes K, Vantrappen G. Tissue damage produced by hemostatic injections Gastrointest Endosc, 1986;32:A179
16 Loperfido S, Patelli G, La Torre I. Extensive necrosis of gastric mucosa following injection therapy of bleeding peptic ulcer. Endoscopy, 1990;22:285-286
17 Bedford RA, van Stolk R, Sivak MV. Gastric perforation after endoscopic treatment of a Dieulafoy’s lesion. Am J Gastroenterol, 1992;87:244-247
18 Hayashi T, Yonezawa M, Kuwahara J. The study on stalk clip for the treatment by endoscopy Gastroenterol, 1975;17:92-101
19 Hachisu T. Evaluation of endoscopic hemostasis using an improved clipping apparatus. Surg Endosc, 1988;2:13-17
20 Hachisu T, Yamada H, Satoh SI. Endoscopic clipping with a new rotatable clip-device and a long clip. Dig Endosc, 1996;8:127-133
21 Forrest JAN, Finlayson NDC, Shearnan DJC. Endoscopy in gastrointestinal bleeding. Lancet, 1974;2:394-397
22 Rauws EAJ, Kool G, Bolwerk C. New approaches to endoscopic therapy for a hemostasis upper GI bleed. Scand J Gastroenterol, 1996;31(Suppl 218):116-123
23 Choudari CP, Rajagopal C, Elton RA. Failures of endoscopic therapy for bleeding peptic ulcer: an analysis of risk factors. Am J Gastroenterol, 1994;89:1968-1972
24 Silverstein FE, Gilbert DA, Tedesco FJ. The national ASGE survey on upper gastrointestinal bleeding. Gastrointest Endosc, 1992:27:73-102
25 Borman PC, Theodorou NA, Shuttleworth RD. Importance of hypovolemic shock and endoscopic signs in predicting recurrent hemorrhage from peptic ulceration: a prospective evaluation. Br Med J, 1985;291:245-247
26 Foster DN, Miloszewski KJA, Losowsky MS. Stigmata of recent hemorrhage in diagnosis and prognosis of upper gastrointestinal bleeding. Br Med J, 1978;1:1173-1177
27 Yokohata T, Takeshima H, Fukushima R. Bleeding peptic ulcer: injection or clip. Am J Gastroenterol, 1998;93:1998
28 Ohta S, Yukioka T. Hemostasis with endoscopic hemoclipping for severe gastrointestinal bleeding in critically ill patients. Am J Gastroenterol, 1996;91:701-704
29 Kubka AK, Palmer KR. Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. Br J Surg, 1996;83:461-468
30 Graiwek IM, Jensen DM, Kovacs TOG. An economic analysis of hemostasis techniques in gastrointestinal hemorrhage from peptic ulceration: a prospective evaluation. Gastroenterology, 1985;88:1209-1214

Edited by Wu XN
Proofread by Miao QH